Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

Evelien de Vos-Kerkhof; Dennis R Buis; Maarten H Lequin; Carlien A Bennebroek; Eleonora Aronica; Esther Hulleman; Nitash Zwaveling-Soonawala; Hanneke M van Santen; Antoinette Y N Schouten-van Meeteren

doi:10.3389/fendo.2023.1225734

Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

Evelien de Vos-Kerkhof, Dennis R Buis, Maarten H Lequin, Carlien A Bennebroek, Eleonora Aronica, Esther Hulleman, Nitash Zwaveling-Soonawala, Hanneke M van Santen, Antoinette Y N Schouten-van Meeteren

Group Hulleman

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

Samenvatting

We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.

Originele taal-2	Engels
Pagina's (van-tot)	1225734
Tijdschrift	Frontiers in endocrinology
Volume	14
DOI's	https://doi.org/10.3389/fendo.2023.1225734
Status	Gepubliceerd - 11 okt. 2023

Toegang tot document

10.3389/fendo.2023.1225734

Citeer dit

@article{dc76a7c94bba4732a099d32ab9a0acac,

title = "Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report",

abstract = "We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.",

keywords = "Humans, Female, Child, Adolescent, Craniopharyngioma/complications, Pituitary Neoplasms/complications, Hypothalamus/pathology, Hypopituitarism/pathology",

author = "{de Vos-Kerkhof}, Evelien and Buis, {Dennis R} and Lequin, {Maarten H} and Bennebroek, {Carlien A} and Eleonora Aronica and Esther Hulleman and Nitash Zwaveling-Soonawala and {van Santen}, {Hanneke M} and {Schouten-van Meeteren}, {Antoinette Y N}",

note = "Copyright {\textcopyright} 2023 de Vos-Kerkhof, Buis, Lequin, Bennebroek, Aronica, Hulleman, Zwaveling-Soonawala, van Santen and Schouten-van Meeteren.",

year = "2023",

month = oct,

day = "11",

doi = "10.3389/fendo.2023.1225734",

language = "English",

volume = "14",

pages = "1225734",

journal = "Frontiers in endocrinology",

issn = "1664-2392",

publisher = "Frontiers Media S.A.",

}

TY - JOUR

T1 - Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

AU - de Vos-Kerkhof, Evelien

AU - Buis, Dennis R

AU - Lequin, Maarten H

AU - Bennebroek, Carlien A

AU - Aronica, Eleonora

AU - Hulleman, Esther

AU - Zwaveling-Soonawala, Nitash

AU - van Santen, Hanneke M

AU - Schouten-van Meeteren, Antoinette Y N

PY - 2023/10/11

Y1 - 2023/10/11

N2 - We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.

AB - We present the case of a 15-year-old girl, with a fifth cystic progression of an adamantinomatous craniopharyngioma after multiple surgeries and previous local radiotherapy. She had severe visual impairment, panhypopituitarism including diabetes insipidus, and several components of hypothalamic damage, including morbid obesity and severe fatigue. To prevent further late effects hampering her quality of survival, she was treated biweekly with intravenous tocilizumab, an anti-interleukin-6 agent, which stabilized the cyst for a prolonged time. Based on the biology of adamantinomatous craniopharyngioma, this immune-modulating treatment seems promising for the treatment of this cystic tumor in order to reduce surgery and delay or omit radiotherapy.

KW - Humans

KW - Female

KW - Child

KW - Adolescent

KW - Craniopharyngioma/complications

KW - Pituitary Neoplasms/complications

KW - Hypothalamus/pathology

KW - Hypopituitarism/pathology

U2 - 10.3389/fendo.2023.1225734

DO - 10.3389/fendo.2023.1225734

M3 - Article

C2 - 37886643

SN - 1664-2392

VL - 14

SP - 1225734

JO - Frontiers in endocrinology

JF - Frontiers in endocrinology

ER -

Tocilizumab for the fifth progression of cystic childhood craniopharyngioma-a case report

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit